X. Luan

Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C

Baixuan Xu, Jiahe Tian, Zhanbo Wang, 2022, Frontiers in Oncology.

18F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer

Jinming Yu, S. Yuan, Xiaorong Sun, 2016, European Journal of Nuclear Medicine and Molecular Imaging.

Tumor angiogenesis at baseline identified by 18F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Jinming Yu, X. Qin, S. Yuan, 2021, Journal of Translational Medicine.

A Preclinical Study of an 125I-Labeled PSMA Ligand for Prostate-Cancer Puncture

Jinming Zhang, Baixuan Xu, Xiaojun Zhang, 2022, Pharmaceuticals.

Multiparameter diagnostic model based on 18F-FDG PET metabolic parameters and clinical variables can differentiate nonmetastatic gallbladder cancer and cholecystitis

Baixuan Xu, Shengxin Chen, Xiaodan Xu, 2023, BMC Cancer.

Lymph Node Maximum Uptake of 18F-ALF-NOTA-PRGD2 II PET/CT Predicts Lung Cancer Survival

Y. Pei, X. Qin, S. Yuan, 2020 .

The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

Baixuan Xu, Zhanbo Wang, Guangyu Ma, 2023, Frontiers in Immunology.

PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancer

Jinming Yu, Wei Zhao, S. Yuan, 2020 .

18F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancer

Jinming Yu, Wei Zhao, S. Yuan, 2020, Translational lung cancer research.